Abstract
Pathogenesis of Parkinson’s disease has not been well elucidated yet. However, some hypotheses have been advocated. Mitochondrial abnormalities,1,2,3,4,5,6 and changes of iron and free radicals7,8 have been reported. The mechanism of nigrostriatal degeneration in MPTP-induced parkinsonism appears to be due to the inhibition of mitochondrial respiration by MPP+. 9,10,11,12 Chronic exposure to an unknown MPTP-like endogenous neurotoxin has been postulated as a possible etiology of Parkinson’s disease. 1,2,3,4-Tetrahydroisoquinoline (TIQ) has emerged as one of such toxins.13 We have previously reported the effects of TIQ14,15,16,17 and TIQ-related compounds18 on mitochondrial respiration. In the present study, we report the inhibitory effect of dopamine-derived endogenous tetrahydroisoquinolines against mitochondrial respiration.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A.V. Schapira, J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark and C.D. Marsden, Mitochondria) complex I deficiency in Parkinson’s disease, Lancet 1: 1269 (1989).
Y. Mizuno, K. Suzuki and S. Ohta, Postmortem changes in mitochondria) respiratory enzymes in brain and a preliminary observation in Parkinson’s disease, J. Neurol. Sci. 96: 49 (1990).
Y. Mizuno, S. Ohta, M. Tanaka, S. Takamiya, K. Suzuki, T. Sato, H. Oya, T. Ozawa and Y. Kagawa, Deficiencies in Complex I subunits of the respiratory chain in Parkinson’s disPACe, Biochem. Biophys. Res. Commun. 163: 1450 (1989).
N. Hattori, M. Tanaka, T. Ozawa and Y. Mizuno, Immunohistochemical studies on Complex I, II, III, and IV of mitochondria in Parkinson’s disease, Ann. Neurol. 30: 563 (1991).
S. Ikebe, M. Tanaka, K. Ohno, W. Sato, K. Hattori, T. Kondo, Y. Mizuno and T. Ozawa, Increase of deleted mitochondria) DNA in the striatum in Parkinson’s disease and senescence, Biochem. Biophys. Res. Commun. 170: 1044 (1990).
S. Ikebe, N. Hattori, Y. Mizuno, M. Tanaka and T. Ozawa, Point mutations of mitochondria) DNA in Parkinson’s disease, Mov. Disorder 7 (Supple 1): 71 (1992).
M.B.H. Youdim, D. Ben-Shachar and P. Riederer, Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron-and melanin-induced neurodegeneration? Acta Neurol. Scand. 126: 47 (1989).
D.T. Dexter, A. Carayon, F. Javoy-Agid, Y. Agid, F. R. Wells, S.E. Daniel, A.J. Lees, P. Jenner and C.D. Marsden, Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia, Brain 114: 1953 (1991).
Y. Mizuno, T. Saitoh and N. Sone, Inhibition mitochondria) NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion, Biochem. Biophys. Res. Commun. 143: 294 (1987).
Y. Mizuno, N. Sone and T. Saitoh, Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine and 1methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain, J. Neurochem. 48: 1787 (1987).
Y. Mizuno, N. Sone, K. Suzuki and T. Saitoh, Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP’) against mitochondria of mouse brain, J. Neurol. Sci. 86: 97 (1988).
Y. Mizuno, K. Suzuki, N. Sone and T. Saitoh, Inhibition of mitochondria) respiration by 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo, Neurosci. Leu. 91: 349 (1988).
T. Nagatsu and Y. Hirata, Inhibition of the tyrosine hydroxylase system by MPTP, 1- methyl-4phenylpyridinium ion (MPP+) and the structurally related compounds in vitro and in vivo, Eur. Neurol. 26 (suppl. 1): 11 (1987).
K. Suzuki, Y. Mizuno and M. Yoshida, Inhibition of mitochondria) NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline, Neurosci. Leu. 86: 105 (1988).
K. Suzuki, Y. Mizuno and M. Yoshida, Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline, Biochem. Biophys. Res. Commun. 162: 1541 (1989).
K. Suzuki, Y. Mizuno and M. Yoshida, Inhibition of mitochondria) respiration by 1,2,3,4tetrahydroisoquinoline-like endogenous alkaloids in mouse brain, Neurochem. Res. 15: 705 (1990).
K. Suzuki, Y. Mizuno and M. Yoshida, Effects of tetrahydroisoquinoline on mitochondrial respiration, in: “Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases”, T. Nagatsu et al. ed., Plenum Press, New York Vol. 1, p. 309, (1990).
K. Suzuki, Y. Mizuno, Y. Yamauchi, T. Nagatsu and M. Yoshida, Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquino-line in isolated mitochondria prepared from mouse brain, J. Neurol. Sci. 109: 219 (1992).
T. Niwa, N. Takeda, N. Kaneda, Y. Hashizume and T. Nagatsu, Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroisoquinoline in parkinsonian and human brains, Biochem. Biophys. Res. Commun. 144: 1084 (1987).
S. Ohta, M. Kohno, Y. Makino, O. Tachikawa and M. Hirobe, Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: relation to Parkinson’s disease, Biomed. Res. 8: 453 (1987).
Y. Makin, S. Ohta, O. Tachikawa and M. Hirobe, Presence of tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline in foods: compounds related to Parkinson’s disease, Life Sci. 43: 373 (1988).
T. Nagatsu and M. Yoshida, An endogenous substance of the brain, tetrahydroisoquino-line, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions, Neuro. Sci. Lett. 87: 178 (1988).
T. Niwa, N. Takeda, A. Tatematsu, S. Matsumura, M. Yoshida and T. Nagatsu, Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood is proved by gas chromatography-mass spectrometry, J. Chromatogr. 452: 85 (1988).
M. Naoi, S. Matsumura, T. Takahashi and T. Nagatsu, A N-methyl-transferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion, Biochem. Biophys. Res. Commun. 161: 1213 (1989).
M. Naoi, S. Matsuura, H. Parvez, T. Takahashi, Y. Hirata, M. Minami and T. Nagatsu, Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinolineinto the N-methylisoquino-linium ion by monoamine oxidase, J. Neurochem. 52: 653 (1989).
P. Dostert, M.S. Benedetti and G. Dordain, Tetrahydroisoquinoline alkaloids in neurodegenerative disorders - influence of drug treatment, in: “Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases”, Vol. 1, p. 247, T. Nagatsu et al. ed., Plenum Press, New York (1990).
W. Maruyama, D. Nakahara, M. Ota, T. Takahashi, A. Takahashi, T. Nagatsu and M. Naoi, Nmethylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroiso-quinoline, (R)-salsolinol, in rat brains: in vivo microdialysis study, J. Neurochem. 59:395 (1992).
T. Niwa, N. Takeda, H. Yoshizumi, A. Tatematsu, M. Yoshida, P. Dostert, M. Naoi and T. Nagatsu, Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolineand 1,2-dimethyl-6,7dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains, Biochem. Biophys. Res. Commun. 177: 603 (1991).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Suzuki, K., Mizuno, Y., Naoi, M., Nagatsu, T., Yoshida, M. (1995). Inhibitory Effects of Endogenous Tetrahydroisoquinolines on Mitochondrial Respiration in Mouse Brain. In: Hanin, I., Yoshida, M., Fisher, A. (eds) Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 44. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9145-7_82
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9145-7_82
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9147-1
Online ISBN: 978-1-4757-9145-7
eBook Packages: Springer Book Archive